Literature DB >> 26077043

Gastrointestinal cancer: Management of GIST--go beyond imatinib: treat resistant subtypes.

Maria A Pantaleo1, Guido Biasco1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26077043     DOI： 10.1038/nrclinonc.2015.107

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

Review 1.  Gastrointestinal stromal tumours: origin and molecular oncology.

Authors:  Christopher L Corless; Christine M Barnett; Michael C Heinrich
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

2.  Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Diana Griffith; Arin McKinley; Janice Patterson; Ajia Presnell; Abhijit Ramachandran; Maria Debiec-Rychter
Journal:  Clin Cancer Res       Date:  2012-06-27       Impact factor: 12.531

3.  Heterogeneity of kinase inhibitor resistance mechanisms in GIST.

Authors:  B Liegl; I Kepten; C Le; M Zhu; G D Demetri; M C Heinrich; C D M Fletcher; C L Corless; J A Fletcher
Journal:  J Pathol       Date:  2008-09       Impact factor: 7.996

4.  Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.

Authors:  Jean-Yves Blay; Lin Shen; Yoon-Koo Kang; Piotr Rutkowski; Shukui Qin; Dmitry Nosov; Desen Wan; Jonathan Trent; Vichien Srimuninnimit; Zsuzsanna Pápai; Axel Le Cesne; Steven Novick; Lilia Taningco; Shuyuan Mo; Steven Green; Peter Reichardt; George D Demetri
Journal:  Lancet Oncol       Date:  2015-04-14       Impact factor: 41.316

5.  Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations.

Authors:  Maria A Pantaleo; Cristian Lolli; Margherita Nannini; Annalisa Astolfi; Valentina Indio; Maristella Saponara; Milena Urbini; Stefano La Rovere; Antony Gill; David Goldstein; Claudio Ceccarelli; Donatella Santini; Giulio Rossi; Michelangelo Fiorentino; Valerio Di Scioscio; Pietro Fusaroli; Anna Mandrioli; Lidia Gatto; Fausto Catena; Umberto Basso; Giorgio Ercolani; Antonio Daniele Pinna; Guido Biasco
Journal:  Genet Med       Date:  2014-09-04       Impact factor: 8.822

6.  Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper.

Authors:  P G Casali; P Bruzzi; J Bogaerts; J-Y Blay
Journal:  Ann Oncol       Date:  2014-10-01       Impact factor: 32.976

7.  Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines.

Authors:  Hans Prenen; Gunther Guetens; Gert de Boeck; Maria Debiec-Rychter; Paul Manley; Patrick Schoffski; Allan T van Oosterom; Ernst de Bruijn
Journal:  Pharmacology       Date:  2006-03-08       Impact factor: 2.547

8.  BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.

Authors:  G S Falchook; J C Trent; M C Heinrich; C Beadling; J Patterson; C C Bastida; S C Blackman; R Kurzrock
Journal:  Oncotarget       Date:  2013-02
  8 in total
  2 in total

1.  The rs17084733 variant in the KIT 3' UTR disrupts a miR-221/222 binding site in gastrointestinal stromal tumour: a sponge-like mechanism conferring disease susceptibility.

Authors:  Gloria Ravegnini; César Serrano; Vittorio Simeon; Giulia Sammarini; Margherita Nannini; Erica Roversi; Milena Urbini; Fabrizio Ferrè; Riccardo Ricci; Giuseppe Tarantino; Maria A Pantaleo; Patrizia Hrelia; Sabrina Angelini
Journal:  Epigenetics       Date:  2019-04-13       Impact factor: 4.528

Review 2.  Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice.

Authors:  Matteo Fassan; Aldo Scarpa; Andrea Remo; Giovanna De Maglio; Giancarlo Troncone; Antonio Marchetti; Claudio Doglioni; Giuseppe Ingravallo; Giuseppe Perrone; Paola Parente; Claudio Luchini; Luca Mastracci
Journal:  Pathologica       Date:  2020-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.